WHO Model Prescribing Information: Drugs Used in Anaesthesia
(1989; 60 pages) [French] Voir le document au format PDF
Table des matières
Afficher le documentPreface
Afficher le documentIntroduction
Ouvrir ce répertoire et afficher son contenuPremedication
Ouvrir ce répertoire et afficher son contenuGeneral anaesthetics and oxygen
Ouvrir ce répertoire et afficher son contenuLocal anaesthetics
Fermer ce répertoireNon-opioid analgesics
Afficher le documentAcetylsalicylic acid
Afficher le documentParacetamol
Ouvrir ce répertoire et afficher son contenuOpioid analgesics and antagonists
Ouvrir ce répertoire et afficher son contenuMuscle relaxants and cholinesterase inhibitors
Ouvrir ce répertoire et afficher son contenuBlood substitutes
Ouvrir ce répertoire et afficher son contenuSolutions for correcting water and electrolyte imbalance
Ouvrir ce répertoire et afficher son contenuAntacid for use in obstetric practice
Afficher le documentAnaesthesia at the District Hospital
Afficher le documentSelected WHO publications of related interest
Afficher le documentBack cover

Acetylsalicylic acid

Group: non-opioid analgesic
Tablet: 100-500 mg
Suppository: 50-150 mg

General information

Acetylsalicylic add has anti-inflammatory, analgesic, antipyretic, antirheumatic and antithrombotic activity. In part these effects are due to inhibition of the synthesis of endogenous prostaglandins.

It is hydrolysed primarily in the gut and the liver and excreted mainly in the urine, both as free salicylic acid and as inactive metabolites. The plasma half-life of salicylate resulting from doses of 2-3 g of acetylsalicylic acid is approximately 3 hours. With higher doses it is significantly longer.

Clinical information


Symptomatic relief of mild to moderate pain.

Dosage and administration

Adults: 300-900 mg every 4-6 hours as required (max 4 g/day).


6-12 years: 300-400 mg every 6 hours.
3-5 years: 200-300 mg every 8 hours.
1-2 years: 50-150 mg every 6 hours.

Treatment should not be continued for more than 5 days except on medical advice.

Administration with food or a full glass of water reduces gastric irritation. Rectal absorption is slow and incomplete, but suppositories are of value in patients unable to take oral dosage forms.


• Hypersensitivity to acetylsalicylic acid.

• Bleeding disorders, anticoagulant therapy, haemorrhagic stroke, active peptic ulcer or gastritis.

• Chronic renal insufficiency.

Reye’s syndrome (a rare but often fatal non-inflammatory encephalopathy and fatty metamorphosis of the liver) has been reported in children and adolescents with influenza or chickenpox who have received acetylsalicylic acid. The risk is remote but it is readily avoided by withholding the drug in these circumstances.

To avoid the risk of haemorrhage acetylsalicylic acid should not be administered within 7 days of an elective surgical operation.


Symptoms of hypersensitivity are more likely to occur in:

• patients with asthma, urticaria or chronic rhinitis

• patients who have developed skin rashes or anaphylactic phenomena after exposure to other nonsteroidal anti-inflammatory agents.

A mild haemolytic reaction may occur in patients with glucose-6-phosphate dehydrogenase deficiency.

Young children are particularly susceptible to the dose-related toxic effects of acetylsalicylic acid. They should never receive more than the maximum recommended dose and stocks of tablets should never be left within their reach.

Use in pregnancy

Normal use of acetylsalicylic add carries no apparent risk during early pregnancy. However, it should not be taken in the last 3 months of pregnancy since it has been reported to prolong labour and contribute to maternal and neonatal bleeding.

Adverse effects

Hypersensitivity reactions, which may occasionally be severe, include urticaria, angio-oedema, pruritus and anaphylactic phenomena.

Gastrointestinal effects including dyspepsia, heartburn, epigastric distress and nausea are common and sometimes severe. Gastrointestinal bleeding can result from acute mucosal erosion or reactivation of peptic ulceration. It is commonly occult but occasionally profuse and even fatal.

Inhibition of platelet aggregation may result in prolongation of bleeding time. Leukopenia, thrombocytopenia, purpura and pancytopenia have rarely been reported.

Drug interactions

The therapeutic actions of anticoagulants may be potentiated.

Conversely, the efficacy of uricosuric agents and spironolactone may be reduced.

Co-administration of acetylsalicylic acid and corticosteroids greatly increases the risk of gastrointestinal bleeding.


Acute ingestion of 20-25 g by an adult, or 4 g by a small child, can be lethal and smaller quantities can cause serious toxic effects.

Characteristic early signs of overdosage include nausea and vomiting, abdominal pain and tinnitus that may ultimately progress to deafness. These are followed by flushing, sweating and hyperventilation with respiratory alkalosis. In severe cases metabolic acidosis and coma supervene.

Gastric lavage should be carried out immediately. Failing this, vomiting should be induced. Hyperthermia, dehydration, acidosis and potassium deficiency should be corrected symptomatically.

Whole blood transfusion may be necessary in the event of spontaneous haemorrhage. It is unnecessary additionally to prescribe vitamin K routinely.

Forced alkaline diuresis accelerates excretion of salicylate. However, when the serum salicylate concentration is dangerously high or when grave signs develop, such as unresponsive acidosis, impaired urinary output, pulmonary oedema, persistent seizures or coma, haemodialysis may offer the only hope of survival.


Acetylsalicylic add tablets should be kept in tightly closed containers. If an odour of acetic acid is perceptible on opening the container, the tablets should be discarded. Suppositories should be stored below 15°C.

vers la section précédente
vers la section suivante
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 29 octobre 2018